Brief: Transgene Reports End-September Cash And Cash Equivalents Of EUR 45.3 Million

Transgene SA

05/11/2020 16:57

Nov 5 (Reuters) - Transgene SA  TRNG.PA :
    * TRANSGENE REPORTS BUSINESS UPDATE AND END Q3 2020
FINANCIAL
POSITION
    * EUR 45.3 MILLION IN CASH AND CASH EQUIVALENTS AS OF
SEPTEMBER
30, 2020, FOLLOWING PARTIAL SALE OF STAKE IN TASLY
BIOPHARMACEUTICALS
    * PROMISING CLINICAL DATA FOR TG4001 - LATE BREAKER ABSTRACT
AT
SITC 2020
    * ADVANCED TECHNOLOGICAL LEADERSHIP WITH THEMYVAC® PLATFORM:
TWO
CLINICAL TRIALS IN PATIENTS WITH SOLID TUMORS INITIATED IN
JANUARY 2020
    * INITIAL TRANSLATIONAL DATA CONFIRM THAT I.V. TG6002 CAN
INDUCE
PRODUCTION OF A CHEMOTHERAPY AGENT (5-FU) IN TUMOR

Source text for Eikon:  ID:nNDL4pBCXW 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))